Table 1.
Characteristics among women in the RA subcohort by exposures (not mutually exclusive), n = 528
| Any exposure after gestational day 139a | ||||||
|---|---|---|---|---|---|---|
| Oral corticosteroid | B-DMARD | NB-DMARD | ||||
| Yes | No | Yes | No | Yes | No | |
| Characteristic | n=250 | n=278 | n=208 | n=320 | n=96 | n=432 |
| LMP Year 2009–2014, n (%) | 121 (48.4) | 155 (55.8) | 118 (56.7) | 158 (49.4) | 65 (67.7) | 211 (48.8) |
| Maternal age, mean (SD) | 32.3 (4.6) | 32.3 (4.7) | 32.6 (4.5) | 32.1 (4.7) | 32.3 (4.6) | 32.3 (4.6) |
| Non-Hispanic White, n (%) | 196 (78.4) | 221 (79.5) | 174 (83.7) | 243 (75.9) | 76 (79.2) | 341 (78.9) |
| Socioeconomic status, Hollingshead categories 1 or 2b, n (%) | 197 (78.8) | 213 (76.6) | 166 (79.8) | 244 (76.3) | 74 (77.1) | 336 (77.8) |
| Primiparous, n (%) | 120 (48.0) | 129 (46.4) | 99 (47.6) | 150 (46.9) | 42 (43.8) | 207 (47.9) |
| Multiple gestation, n (%) | 16 (6.4) | 7 (2.5) | 11 (5.3) | 12 (3.8) | 2 (2.1) | 21 (4.9) |
| ≥5 servings of alcohol in the first trimester, n (%) | 41 (16.4) | 56 (20.1) | 28 (13.5) | 69 (21.6) | 14 (14.6) | 83 (19.2) |
| First trimester cigarette smoking, n (%) | 14 (5.6) | 19 (6.8) | 9 (4.3) | 24 (7.5) | 4 (4.2) | 29 (6.7) |
| Pre-pregnancy hypertension, n (%) | 20 (8.0) | 17 (6.1) | 20 (9.6) | 17 (5.3) | 11 (11.5) | 26 (6.0) |
| IBD, lupus, or ankylosing spondylitis, n (%) | 16 (6.4) | 13 (4.7) | 15 (7.2) | 14 (4.4) | 3 (3.1) | 26 (6.0) |
| NSAID use before gestational day 110, n (%) | 102 (40.8) | 86 (30.9) | 76 (36.5) | 112 (35.0) | 41 (42.7) | 147 (34.0) |
| Oral corticosteroid use before gestational day 110, n (%) | 205 (82.0) | 39 (14.0) | 83 (39.9) | 161 (50.3) | 53 (55.2) | 191 (44.2) |
| B-DMARD use before gestational day 110, n (%) | 172 (68.8) | 183 (65.8) | 207 (99.5) | 148 (46.3) | 63 (65.6) | 292 (67.6) |
| NB-DMARD use before gestational day 110, n (%) | 88 (35.2) | 71 (25.5) | 58 (27.9) | 101 (31.6) | 88 (91.7) | 71 (16.4) |
| HAQ at enrollment, mean (SD)c | 0.67 (0.67) | 0.40 (0.52) | 0.49 (0.60) | 0.56 (0.62) | 0.47 (0.58) | 0.54 (0.62) |
| Pain score at enrollment, mean (SD)d | 34.4 (29.5) | 23.7 (25.3) | 27.2 (27.7) | 29.7 (28.0) | 24.8 (26.5) | 29.6 (28.2) |
| Global score at enrollment, mean (SD)d | 29.9 (27.1) | 19.9 (23.1) | 22.7 (24.5) | 26.0 (26.2) | 20.5 (22.9) | 25.6 (26.0) |
a
An additional 30 days of exposure was added to reported end dates of use.
b
Calculated using Hollingshead categories based on maternal and paternal education and occupation; Possible Range: 1, highest to 5, lowest. Missing for eight women.
c
Imputed for three women; possible range: 0, no disability to 3, completely disabled.
d
Imputed for two women; pain score possible range: 0, no pain to 100, severe pain; patient’s global score possible range: 0, very well to 100, very poor.
B-DMARD: biologic disease modifying antirheumatic drug; LMP: last menstrual period; NB-DMARD: non-biologic disease modifying antirheumatic drug.